You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia
|
|---|---|
| Published in |
Journal for Immunotherapy of Cancer, December 2016
|
| DOI | 10.1186/s40425-016-0188-z |
| Pubmed ID | |
| Authors |
Michael Boyiadzis, Michael R. Bishop, Rafat Abonour, Kenneth C. Anderson, Stephen M. Ansell, David Avigan, Lisa Barbarotta, Austin John Barrett, Koen Van Besien, P. Leif Bergsagel, Ivan Borrello, Joshua Brody, Jill Brufsky, Mitchell Cairo, Ajai Chari, Adam Cohen, Jorge Cortes, Stephen J. Forman, Jonathan W. Friedberg, Ephraim J. Fuchs, Steven D. Gore, Sundar Jagannath, Brad S. Kahl, Justin Kline, James N. Kochenderfer, Larry W. Kwak, Ronald Levy, Marcos de Lima, Mark R. Litzow, Anuj Mahindra, Jeffrey Miller, Nikhil C. Munshi, Robert Z. Orlowski, John M. Pagel, David L. Porter, Stephen J. Russell, Karl Schwartz, Margaret A. Shipp, David Siegel, Richard M. Stone, Martin S. Tallman, John M. Timmerman, Frits Van Rhee, Edmund K. Waller, Ann Welsh, Michael Werner, Peter H. Wiernik, Madhav V. Dhodapkar |
| Abstract |
Increasing knowledge concerning the biology of hematologic malignancies as well as the role of the immune system in the control of these diseases has led to the development and approval of immunotherapies that are resulting in impressive clinical responses. Therefore, the Society for Immunotherapy of Cancer (SITC) convened a hematologic malignancy Cancer Immunotherapy Guidelines panel consisting of physicians, nurses, patient advocates, and patients to develop consensus recommendations for the clinical application of immunotherapy for patients with multiple myeloma, lymphoma, and acute leukemia. These recommendations were developed following the previously established process based on the Institute of Medicine's clinical practice guidelines. In doing so, a systematic literature search was performed for high-impact studies from 2004 to 2014 and was supplemented with further literature as identified by the panel. The consensus panel met in December of 2014 with the goal to generate consensus recommendations for the clinical use of immunotherapy in patients with hematologic malignancies. During this meeting, consensus panel voting along with discussion were used to rate and review the strength of the supporting evidence from the literature search. These consensus recommendations focus on issues related to patient selection, toxicity management, clinical endpoints, and the sequencing or combination of therapies. Overall, immunotherapy is rapidly emerging as an effective therapeutic strategy for the management of hematologic malignances. Evidence-based consensus recommendations for its clinical application are provided and will be updated as the field evolves. |
X Demographics
The data shown below were collected from the profiles of 31 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 12 | 39% |
| Spain | 4 | 13% |
| Chile | 2 | 6% |
| Switzerland | 1 | 3% |
| Mexico | 1 | 3% |
| Australia | 1 | 3% |
| Unknown | 10 | 32% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 22 | 71% |
| Practitioners (doctors, other healthcare professionals) | 6 | 19% |
| Scientists | 1 | 3% |
| Science communicators (journalists, bloggers, editors) | 1 | 3% |
| Unknown | 1 | 3% |
Mendeley readers
The data shown below were compiled from readership statistics for 83 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 83 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 12 | 14% |
| Other | 11 | 13% |
| Student > Ph. D. Student | 9 | 11% |
| Student > Master | 5 | 6% |
| Student > Postgraduate | 4 | 5% |
| Other | 16 | 19% |
| Unknown | 26 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 26 | 31% |
| Biochemistry, Genetics and Molecular Biology | 6 | 7% |
| Immunology and Microbiology | 5 | 6% |
| Nursing and Health Professions | 4 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 5% |
| Other | 11 | 13% |
| Unknown | 27 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 479. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 June 2022.
All research outputs
#55,695
of 25,394,764 outputs
Outputs from Journal for Immunotherapy of Cancer
#7
of 3,428 outputs
Outputs of similar age
#1,224
of 423,086 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#3
of 31 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,428 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.4. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 423,086 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 31 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.